A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT04881760
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3437943 — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

Key Dates

Start date
May 20, 2021
Status verified
Aug 2023
Primary completion
May 16, 2022
Completion
Nov 22, 2022

Study Design

Enrollment
338 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
  • Experimental: 1 milligram (mg) LY3437943
    Participants received 1 mg LY3437943 administered as SC injection QW.
  • Experimental: 4 mg LY3437943 (2 mg)
    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
  • Experimental: 4 mg LY3437943
    Participants received 4 mg LY3437943 administered as SC injection QW.
  • Experimental: 8 mg LY3437943 (2 mg)
    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
  • Experimental: 8 mg LY3437943 (4 mg)
    Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
  • Experimental: 12 mg LY3437943 (2 mg)
    Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

Primary Outcome Measure

Mean Percent Change From Baseline in Body Weight [ Time Frame: Baseline, Week 24 ]

Locations (25)

FacilityCityStateZIPSite coordinators
Perseverance Research CenterScottsdaleArizona85254-
Anaheim Clinical Trials, LLCAnaheimCalifornia92801-
Valley ResearchFresnoCalifornia93720-
Velocity Clinical Research, Huntington ParkHuntington ParkCalifornia90255-
Velocity Clinical Research, Huntington ParkLos AngelesCalifornia90057-
Southern California Dermatology, Inc.Santa AnaCalifornia92701-
Coastal Metabolic Research CentreVenturaCalifornia93003-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
East Coast Institute for Research, LLCJacksonvilleFlorida32216-
Suncoast Clinical Research, Inc.New Port RicheyFlorida34652-
Encore Medical Research - WestonWestonFlorida33331-
Springfield Diabetes & Endocrine CenterSpringfieldIllinois62711-
Cotton O'Neil Diabetes and Endocrinology CenterTopekaKansas66606-
Tandem Clinical Research,LLCMarreroLouisiana70072-
StudyMetrix ResearchCity of Saint PetersMissouri63303-
Amici Clinical Research LLCRaritanNew Jersey08869-
Intend Research, LLCNormanOklahoma73069-
Allegheny Endocrinology AssociatesPittsburghPennsylvania15212-
New Phase Research and DevelopmentKnoxvilleTennessee37909-
Texas Diabetes & Endocrinology, P.A.AustinTexas78731-
Dallas Diabetes Research CenterDallasTexas75230-
Endocrine Ips, PllcHoustonTexas77079-
Juno ResearchHoustonTexas77054-
Southern Endocrinology AssociatesMesquiteTexas75149-
Rainier Clinical Research CenterRentonWashington98057-

Find similar trials in Scottsdale, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Perseverance Research Center· Scottsdale, AZAnaheim Clinical Trials, LLC· Anaheim, CAValley Research· Fresno, CAVelocity Clinical Research, Huntington Park· Huntington Park, CAVelocity Clinical Research, Huntington Park· Los Angeles, CASouthern California Dermatology, Inc.· Santa Ana, CA

Related Studies